|
Status of rituximab in multiple
sclerosis
Click
here to view or print this bulletin in its
original format.
Medical Update Memo
January 20, 2006
Recent media reports have suggested that
an agent called rituximab (Rituxan®, by Genentech)
may be an effective therapy for multiple sclerosis. Rituxumab
is currently being studied in a multi-centre Phase II/III trial
involving primary-progressive MS, and a Phase II trial in secondary-progressive
MS, and results from these studies are not yet available. Although
there was a case report recently published (Stuve et al, Arch
Neurol. 2005; 62:1620-1623) about one person who did well
after receiving this agent, there is insufficient data to determine
whether this agent is safe and effective for treating multiple
sclerosis. We are awaiting the results of larger, controlled
trials that are currently under way.
About Rituximab: This agent, which is given
as an infusion into the vein, binds to a molecule (CD20) on
the surface of B cells and depletes them from the circulation.
B cells are immune cells that make antibodies and may play
a role in the immune attack on brain and spinal cord tissues
in multiple sclerosis. Rituximab is approved for treating some
forms of cancer, and is under testing for several autoimmune
diseases including lupus erythematosus, rheumatoid arthritis
and multiple sclerosis. Beyond the larger-scale studies, the
National MS Society (USA) is currently supporting a small clinical
trial of rituximab by Dr. Anne H. Cross at Washington University
in St. Louis. This trial involves individuals with relapsing-remitting
MS, and is still ongoing.
- Adapted from information from the National
MS Society (USA)
ASK MS Information System Code:
1.4.1.12.2.
Disclaimer
The Multiple Sclerosis Society of Canada is an independent,
voluntary health agency and does not approve, endorse or
recommend any specific product or therapy but provides
information to assist individuals in making their own decisions.
|
